Latest Content

Patient-reported outcomes from the phase 3 lidERA trial show preserved functioning and less frequent joint pain with giredestrant vs standard endocrine therapy.

Arcotatug tavatecan improved PFS and OS vs physician’s choice in previously treated, CLDN18.2-positive advanced gastric and GEJ cancer.

Exploratory subgroup analyses of the phase 2 DOVACC trial suggested a possible signal with the triplet in HRD-negative and PARP inhibitor–naive disease.

Perioperative nivolumab plus neoadjuvant chemotherapy did not significantly improve pCR rate or event-free survival in MIBC.

A protein called MPP8 helps drive chemotherapy resistance in the most-aggressive subtype of breast cancer, and suppressing its expression has the potential to improve treatment outcomes.

Overall survival benefit of daraxonrasib vs chemotherapy extends across RAS genotypes, chemotherapy regimens, and prior treatment settings.

MajesTEC-9 data supported an EU indication expansion for teclistamab in relapsed/refractory multiple myeloma.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Readers share their opinions on some of the most talked-about lung cancer abstracts they’re looking forward to seeing at ESMO 2026.

Gastrointestinal oncologists weigh HER2 testing practices, the order of HER2-directed therapies, and emerging agents for metastatic colorectal cancer.

The FDA has granted traditional approval to pembrolizumab for unresectable/metastatic TMB-H solid tumors.

The FDA granted fast track designation to SBE303 for locally advanced or metastatic urothelial cancer previously treated with enfortumab vedotin.

The oral PLK1 inhibitor onvansertib received FDA orphan drug designation in CMML.

Phase 1 data support continued investigation of roginolisib in advanced cancers, including metastatic uveal melanoma.

Two MD Anderson Cancer Center researchers were elected to the National Academy of Medicine for contributions to cancer care and research.

Breast cancer experts address frequently asked questions on adjuvant and metastatic CDK4/6 inhibitor selection in HR-positive breast cancer.

The European Commission approved pembrolizumab plus enfortumab vedotin for muscle-invasive bladder cancer, irrespective of cisplatin eligibility.

Thoracic oncologists weigh how TROP2-directed antibody-drug conjugates fit into sequencing and combination strategies for EGFR-mutated NSCLC.

Patients with pancreatic cancer experience measurable changes in body composition years before diagnosis that differ from those seen in similar individuals without cancer.

Lisaftoclax plus acalabrutinib earned breakthrough therapy status in China for untreated CLL/SLL.

Andrea Cercek, MD, discusses the FDA approval of dostarlimab and its significance for dMMR locally advanced rectal cancer management.

Fadi Haddad, MD, discusses TKI adherence barriers, adverse effect management, and the role of alternative TKI formulations in CML.

Updated ARC-20 data showed casdatifan activity as monotherapy and in combinations across treatment lines in advanced clear cell RCC.

The designation covers QTX3034 plus cetuximab with or without FOLFOX; phase 1 data showed a 25% confirmed ORR with the doublet in CRC and PDAC.

MimiVax and Roswell Park announced phase 2b SURVIVE trial results evaluating the SurVaxM vaccine in newly diagnosed glioblastoma.

Faculty at an OncLive Scientific Interchange and Workshop discussed individualizing frontline immune checkpoint inhibitor selection in metastatic NSCLC.

The FDA granted fast track designation to MC001 for pancreatic cancer.

The NCCN update adds locally advanced CSCC to the category 2A listing that cosibelimab received for metastatic disease in 2025.

In TASKIN, the 12-month OS rate was 61.3% with vilamakitug vs 55.7% with placebo plus trifluridine/tipiracil.

The 510(k) clearance covers an MRI-derived AI risk score for stage I to IIIA disease; the high-risk category carried an HR of 2.81 for recurrence.

The FDA has approved dostarlimab for MSI-H or dMMR locally advanced rectal cancer.

The FDA accepted an NDA for UGN-103 for recurrent low-grade intermediate-risk NMIBC, with a target action date of June 14, 2027.

Ulrich Steidl, MD, PhD, has finalized his Montefiore Einstein Comprehensive Cancer Center senior leadership team.

The CirCLIQ Injector approval for subcutaneous isatuximab in multiple myeloma is the first anticancer treatment delivered via an on-body injector in Japan.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.

Moh’d Khushman, MD, discusses INCA33890’s mechanism of action, phase 1 safety and efficacy data, and the design of NEXERA-303 in MSS colorectal cancer.

The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.

The CHMP opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months.

Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.

Researchers in a Mayo Clinic-led study have shown how to detect a broad range of DNA mutations in noncancerous human tissues and across the genome.

Nunnery and Bond discuss how patients and advocates can navigate second opinions, mental health support, and the long-term effects of cancer treatment.

The CHMP opinion is backed by phase 3 MonumenTAL-3 data evaluating talquetamab plus daratumumab in relapsed/refractory multiple myeloma.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.